CHMP Nod For Ipsen's Mainstay Cancer Drug Cabometyx In First-Line RCC
The EMA's drug assessment committee, the CHMP, has given Ipsen's Cabometyx a positive recommendation for use in first-line kidney cancer, a label extension that will add more weight to the company's standing as a cancer specialist.
You may also be interested in...
The failure of a Cotellic/Tecentriq combo in the IMblaze370 trial highlights Exelixis' dependence on its renal cell carcinoma drug CaboMetyx and the treatment challenges of the aggressive and difficult-to-treat disease that is metastatic colorectal cancer.
Ipsen let French peer Servier buy Shire's oncology assets, including rights for Onivyde in Europe, to concentrate on its coming Cabometyx EU launch and ongoing launch of Onivyde in the US.
Ipsen's chief medical officer Sotirios Stergiopoulos talks about the company's R&D and licensing strategy that he hopes will push Ipsen's oncology unit to the next level.